Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
The global Antivenom market was valued at US$ 903.6 million in 2020 and is expected to reach US$ 1057.6 million by the end of 2029, growing at a CAGR of 2.5% during 2021-2029.
This report focuses on Antivenom volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Antivenom market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Antivenom Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2029. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Polyvalent antivenom
Monovalent antivenom
Segment by Application
Non-profit Institutions
Hospitals and Clinic
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
1 Antivenom Market Overview
1.1 Product Overview and Scope of Antivenom
1.2 Antivenom Segment by Type
1.2.1 Global Antivenom Sales Growth Rate Comparison by Type (2021-2029)
1.2.2 Polyvalent antivenom
1.2.3 Monovalent antivenom
1.3 Antivenom Segment by Application
1.3.1 Global Antivenom Sales Comparison by Application: (2021-2029)
1.3.2 Non-profit Institutions
1.3.3 Hospitals and Clinic
1.4 Global Antivenom Market Size Estimates and Forecasts
1.4.1 Global Antivenom Revenue 2016-2029
1.4.2 Global Antivenom Sales 2016-2029
1.4.3 Antivenom Market Size by Region: 2016 Versus 2021 Versus 2029
2 Antivenom Market Competition by Manufacturers
2.1 Global Antivenom Sales Market Share by Manufacturers (2016-2021)
2.2 Global Antivenom Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Antivenom Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Antivenom Manufacturing Sites, Area Served, Product Type
2.5 Antivenom Market Competitive Situation and Trends
2.5.1 Antivenom Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Antivenom Players Market Share by Revenue
2.5.3 Global Antivenom Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antivenom Retrospective Market Scenario by Region
3.1 Global Antivenom Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Antivenom Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Antivenom Market Facts & Figures by Country
3.3.1 North America Antivenom Sales by Country
3.3.2 North America Antivenom Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Antivenom Market Facts & Figures by Country
3.4.1 Europe Antivenom Sales by Country
3.4.2 Europe Antivenom Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Antivenom Market Facts & Figures by Region
3.5.1 Asia Pacific Antivenom Sales by Region
3.5.2 Asia Pacific Antivenom Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Antivenom Market Facts & Figures by Country
3.6.1 Latin America Antivenom Sales by Country
3.6.2 Latin America Antivenom Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Antivenom Market Facts & Figures by Country
3.7.1 Middle East and Africa Antivenom Sales by Country
3.7.2 Middle East and Africa Antivenom Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Antivenom Historic Market Analysis by Type
4.1 Global Antivenom Sales Market Share by Type (2016-2021)
4.2 Global Antivenom Revenue Market Share by Type (2016-2021)
4.3 Global Antivenom Price by Type (2016-2021)
5 Global Antivenom Historic Market Analysis by Application
5.1 Global Antivenom Sales Market Share by Application (2016-2021)
5.2 Global Antivenom Revenue Market Share by Application (2016-2021)
5.3 Global Antivenom Price by Application (2016-2021)
6 Key Companies Profiled
6.1 CSL
6.1.1 CSL Corporation Information
6.1.2 CSL Description and Business Overview
6.1.3 CSL Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.1.4 CSL Antivenom Product Portfolio
6.1.5 CSL Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Merck Antivenom Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 BTG
6.3.1 BTG Corporation Information
6.3.2 BTG Description and Business Overview
6.3.3 BTG Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.3.4 BTG Antivenom Product Portfolio
6.3.5 BTG Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Pfizer Antivenom Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Haffkine Bio-Pharmaceutical
6.5.1 Haffkine Bio-Pharmaceutical Corporation Information
6.5.2 Haffkine Bio-Pharmaceutical Description and Business Overview
6.5.3 Haffkine Bio-Pharmaceutical Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Haffkine Bio-Pharmaceutical Antivenom Product Portfolio
6.5.5 Haffkine Bio-Pharmaceutical Recent Developments/Updates
6.6 Rare Disease Therapeutics
6.6.1 Rare Disease Therapeutics Corporation Information
6.6.2 Rare Disease Therapeutics Description and Business Overview
6.6.3 Rare Disease Therapeutics Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Rare Disease Therapeutics Antivenom Product Portfolio
6.6.5 Rare Disease Therapeutics Recent Developments/Updates
6.7 Flynn Pharma
6.6.1 Flynn Pharma Corporation Information
6.6.2 Flynn Pharma Description and Business Overview
6.6.3 Flynn Pharma Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Flynn Pharma Antivenom Product Portfolio
6.7.5 Flynn Pharma Recent Developments/Updates
6.8 Vins Bioproducts
6.8.1 Vins Bioproducts Corporation Information
6.8.2 Vins Bioproducts Description and Business Overview
6.8.3 Vins Bioproducts Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Vins Bioproducts Antivenom Product Portfolio
6.8.5 Vins Bioproducts Recent Developments/Updates
6.9 Bharat Serums and Vaccines
6.9.1 Bharat Serums and Vaccines Corporation Information
6.9.2 Bharat Serums and Vaccines Description and Business Overview
6.9.3 Bharat Serums and Vaccines Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Bharat Serums and Vaccines Antivenom Product Portfolio
6.9.5 Bharat Serums and Vaccines Recent Developments/Updates
6.10 Serum Biotech
6.10.1 Serum Biotech Corporation Information
6.10.2 Serum Biotech Description and Business Overview
6.10.3 Serum Biotech Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Serum Biotech Antivenom Product Portfolio
6.10.5 Serum Biotech Recent Developments/Updates
6.11 MicroPharm
6.11.1 MicroPharm Corporation Information
6.11.2 MicroPharm Antivenom Description and Business Overview
6.11.3 MicroPharm Antivenom Sales, Revenue and Gross Margin (2016-2021)
6.11.4 MicroPharm Antivenom Product Portfolio
6.11.5 MicroPharm Recent Developments/Updates
7 Antivenom Manufacturing Cost Analysis
7.1 Antivenom Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Antivenom
7.4 Antivenom Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Antivenom Distributors List
8.3 Antivenom Customers
9 Antivenom Market Dynamics
9.1 Antivenom Industry Trends
9.2 Antivenom Growth Drivers
9.3 Antivenom Market Challenges
9.4 Antivenom Market Restraints
10 Global Market Forecast
10.1 Antivenom Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Antivenom by Type (2022-2029)
10.1.2 Global Forecasted Revenue of Antivenom by Type (2022-2029)
10.2 Antivenom Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Antivenom by Application (2022-2029)
10.2.2 Global Forecasted Revenue of Antivenom by Application (2022-2029)
10.3 Antivenom Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Antivenom by Region (2022-2029)
10.3.2 Global Forecasted Revenue of Antivenom by Region (2022-2029)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Antivenom Sales (K Vials) Growth Rate Comparison by Type (2021-2029)
Table 2. Global Antivenom Sales (K Vials) Comparison by Application (2021-2029)
Table 3. Global Antivenom Market Size by Region (US$ Million) (2016 VS 2021 VS 2029)
Table 4. Key Manufacturers Antivenom Covered in This Study
Table 5. Global Antivenom Sales (K Vials) of Key Manufacturers (2016-2021)
Table 6. Global Antivenom Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Antivenom Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Antivenom Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Antivenom Average Price (USD/Vial) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Antivenom Manufacturing Sites and Area Served
Table 11. Manufacturers Antivenom Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Antivenom by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antivenom as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Antivenom Sales by Region (2016-2021) & (K Vials)
Table 16. Global Antivenom Sales Market Share by Region (2016-2021)
Table 17. Global Antivenom Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Antivenom Sales by Country (2016-2021) & (K Vials)
Table 19. North America Antivenom Sales Market Share by Country (2016-2021)
Table 20. North America Antivenom Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Antivenom Revenue Market Share by Country (2016-2021)
Table 22. Europe Antivenom Sales by Country (2016-2021) & (K Vials)
Table 23. Europe Antivenom Sales Market Share by Country (2016-2021)
Table 24. Europe Antivenom Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Antivenom Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Antivenom Sales by Region (2016-2021) & (K Vials)
Table 27. Asia Pacific Antivenom Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Antivenom Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Antivenom Revenue Market Share by Region (2016-2021)
Table 30. Latin America Antivenom Sales by Country (2016-2021) & (K Vials)
Table 31. Latin America Antivenom Sales Market Share by Country (2016-2021)
Table 32. Latin America Antivenom Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Antivenom Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Antivenom Sales by Country (2016-2021) & (K Vials)
Table 35. Middle East and Africa Antivenom Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Antivenom Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Antivenom Revenue Market Share by Country (2016-2021)
Table 38. Global Antivenom Sales (K Vials) by Type (2016-2021)
Table 39. Global Antivenom Sales Market Share by Type (2016-2021)
Table 40. Global Antivenom Revenue (Million US$) by Type (2016-2021)
Table 41. Global Antivenom Revenue Share by Type (2016-2021)
Table 42. Global Antivenom Price (USD/Vial) by Type (2016-2021)
Table 43. Global Antivenom Sales (K Vials) by Application (2016-2021)
Table 44. Global Antivenom Sales Market Share by Application (2016-2021)
Table 45. Global Antivenom Revenue (Million US$) by Application (2016-2021)
Table 46. Global Antivenom Revenue Share by Application (2016-2021)
Table 47. Global Antivenom Price (USD/Vial) by Application (2016-2021)
Table 48. CSL Corporation Information
Table 49. CSL Description and Business Overview
Table 50. CSL Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 51. CSL Antivenom Product
Table 52. CSL Recent Developments/Updates
Table 53. Merck Corporation Information
Table 54. Merck Description and Business Overview
Table 55. Merck Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 56. Merck Antivenom Product
Table 57. Merck Recent Developments/Updates
Table 58. BTG Corporation Information
Table 59. BTG Description and Business Overview
Table 60. BTG Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 61. BTG Antivenom Product
Table 62. BTG Recent Developments/Updates
Table 63. Pfizer Corporation Information
Table 64. Pfizer Description and Business Overview
Table 65. Pfizer Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 66. Pfizer Antivenom Product
Table 67. Pfizer Recent Developments/Updates
Table 68. Haffkine Bio-Pharmaceutical Corporation Information
Table 69. Haffkine Bio-Pharmaceutical Description and Business Overview
Table 70. Haffkine Bio-Pharmaceutical Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 71. Haffkine Bio-Pharmaceutical Antivenom Product
Table 72. Haffkine Bio-Pharmaceutical Recent Developments/Updates
Table 73. Rare Disease Therapeutics Corporation Information
Table 74. Rare Disease Therapeutics Description and Business Overview
Table 75. Rare Disease Therapeutics Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 76. Rare Disease Therapeutics Antivenom Product
Table 77. Rare Disease Therapeutics Recent Developments/Updates
Table 78. Flynn Pharma Corporation Information
Table 79. Flynn Pharma Description and Business Overview
Table 80. Flynn Pharma Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 81. Flynn Pharma Antivenom Product
Table 82. Flynn Pharma Recent Developments/Updates
Table 83. Vins Bioproducts Corporation Information
Table 84. Vins Bioproducts Description and Business Overview
Table 85. Vins Bioproducts Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 86. Vins Bioproducts Antivenom Product
Table 87. Vins Bioproducts Recent Developments/Updates
Table 88. Bharat Serums and Vaccines Corporation Information
Table 89. Bharat Serums and Vaccines Description and Business Overview
Table 90. Bharat Serums and Vaccines Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 91. Bharat Serums and Vaccines Antivenom Product
Table 92. Bharat Serums and Vaccines Recent Developments/Updates
Table 93. Serum Biotech Corporation Information
Table 94. Serum Biotech Description and Business Overview
Table 95. Serum Biotech Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 96. Serum Biotech Antivenom Product
Table 97. Serum Biotech Recent Developments/Updates
Table 98. MicroPharm Corporation Information
Table 99. MicroPharm Description and Business Overview
Table 100. MicroPharm Antivenom Sales (K Vials), Revenue (Million US$), Price (USD/Vial) and Gross Margin (2016-2021)
Table 101. MicroPharm Antivenom Product
Table 102. MicroPharm Recent Developments/Updates
Table 103. Production Base and Market Concentration Rate of Raw Material
Table 104. Key Suppliers of Raw Materials
Table 105. Antivenom Distributors List
Table 106. Antivenom Customers List
Table 107. Antivenom Market Trends
Table 108. Antivenom Growth Drivers
Table 109. Antivenom Market Challenges
Table 110. Antivenom Market Restraints
Table 111. Global Antivenom Sales Forecast by Type (2022-2029) & (K Vials)
Table 112. Global Antivenom Sales Market Share Forecast by Type (2022-2029)
Table 113. Global Antivenom Revenue Forecast by Type (2022-2029) & (US$ Million)
Table 114. Global Antivenom Revenue Market Share Forecast by Type (2022-2029)
Table 115. Global Antivenom Sales Forecast by Application (2022-2029) & (K Vials)
Table 116. Global Antivenom Sales Market Share Forecast by Application (2022-2029)
Table 117. Global Antivenom Revenue Forecast by Application (2022-2029) & (US$ Million)
Table 118. Global Antivenom Revenue Market Share Forecast by Application (2022-2029)
Table 119. Global Antivenom Sales Forecast by Region (2022-2029) & (K Vials)
Table 120. Global Antivenom Sales Market Share Forecast by Region (2022-2029)
Table 121. Global Antivenom Revenue Forecast by Region (2022-2029) & (US$ Million)
Table 122. Global Antivenom Revenue Market Share Forecast by Region (2022-2029)
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Antivenom
Figure 2. Global Antivenom Market Share by Type in 2020 & 2029
Figure 3. Polyvalent antivenom Product Picture
Figure 4. Monovalent antivenom Product Picture
Figure 5. Global Antivenom Market Share by Application in 2020 & 2029
Figure 6. Non-profit Institutions
Figure 7. Hospitals and Clinic
Figure 8. Global Antivenom Revenue, (US$ Million), 2016 VS 2021 VS 2029
Figure 9. Global Antivenom Market Size 2016-2029 (US$ Million)
Figure 10. Global Antivenom Sales 2016-2029 (K Vials)
Figure 11. Global Antivenom Market Size Market Share by Region: 2016 VS 20210 VS 2029
Figure 12. Antivenom Sales Share by Manufacturers in 2020
Figure 13. Global Antivenom Revenue Share by Manufacturers in 2020
Figure 14. The Global 5 and 10 Largest Antivenom Players: Market Share by Revenue in 2020
Figure 15. Antivenom Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 16. Global Antivenom Sales Market Share by Region (2016-2021)
Figure 17. Global Antivenom Sales Market Share by Region in 2020
Figure 18. Global Antivenom Revenue Market Share by Region (2016-2021)
Figure 19. Global Antivenom Revenue Market Share by Region in 2020
Figure 20. U.S. Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 21. Canada Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 22. Germany Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. France Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. U.K. Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Italy Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Russia Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. China Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Japan Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. South Korea Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. India Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Australia Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Taiwan Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Indonesia Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Thailand Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Malaysia Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Philippines Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Vietnam Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Mexico Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Brazil Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Argentina Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Turkey Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Saudi Arabia Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. U.A.E Antivenom Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Sales Market Share of Antivenom by Type (2016-2021)
Figure 45. Sales Market Share of Antivenom by Application (2016-2021)
Figure 46. Sales Market Share of Antivenom by Application in 2020
Figure 47. Revenue Share of Antivenom by Application (2016-2021)
Figure 48. Revenue Share of Antivenom by Application in 2020
Figure 49. Manufacturing Cost Structure of Antivenom
Figure 50. Manufacturing Process Analysis of Antivenom
Figure 51. Antivenom Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
The research methodology employed by VICResearch has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of VICResearch. VICResearch’s methodology can be divided into five stages:
Stage 1: Secondary research
The research team first works with magazines, industry trade group, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.
Stage 2: Primary research: interviews with trade sources
After the first stage, the research team conducts large number of face-to-face or telephone interviews with the representative companies operating in the research field. The analysts attempt to obtain a chance to talk with leading players in the field as well as with small companies. The upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers are all included in the interviews. The data gathered during the interview is then carefully checked and compared with the secondary research.
Stage 3: Analysis of the gathered data
The analysis team checks and synthesizes the data gathered during the first two stages. To validate the data, a second series of interviews can be conducted.
Stage 4: Quantitative data
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by VICResearch. The data is based on the estimates obtained during stage 3.
The research team also provides appreciation and analysis of the market and the quantitative data contained in the reports. The data is consequently unique to VICResearch.
Stage 5: Quality control
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the VICResearch’s internal quality process.
Consulting report: +86-15323335301 020-31521856
